Clinical trial
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous…
NCT00375609 · Portola Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00375609 |
|---|---|
| Title | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) |
| Official title | Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT) |
| Lead sponsor | Portola Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | Betrixaban, Enoxaparin |
| Enrollment | 215 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 13, 2006 |
| Last update posted | Aug 7, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: